TROP2-CAR-NK Cells

DRUG2 trials

Sponsors

M.D. Anderson Cancer Center

Conditions

Colorectal CancerMinimal Residual DiseaseSolid Tumors

Phase 1

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

RecruitingNCT06066424

M.D. Anderson Cancer CenterSolid Tumors

Start: 2023-10-24End: 2040-04-30Target: 54Updated: 2025-10-14

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

RecruitingNCT06358430

M.D. Anderson Cancer CenterColorectal Cancer, Minimal Residual Disease

Start: 2024-12-02End: 2029-01-18Target: 42Updated: 2026-01-15

Related Papers

Phase 1 dose escalation and expansion study of TROP2 CAR-engineered IL-15-transduced cord blood-derived NK cells in combination with cetuximab in patients with colorectal cancer (CRC) with minimal residual disease (MRD).

Journal of Clinical Oncology2026-01-10